Literature DB >> 20807960

Efficacy of antidepressants in treating the negative symptoms of chronic schizophrenia: meta-analysis.

Surendra P Singh1, Vidhi Singh, Nilamadhab Kar, Kelvin Chan.   

Abstract

BACKGROUND: Treatment of negative symptoms in chronic schizophrenia continues to be a major clinical issue. AIMS: To analyse the efficacy of add-on antidepressants for the treatment of negative symptoms of chronic schizophrenia.
METHOD: Systematic review and meta-analysis of randomised controlled trials comparing the effect of antidepressants and placebo on the negative symptoms of chronic schizophrenia, measured through standardised rating scales. Outcome was measured as standardised mean difference between end-of-trial and baseline scores of negative symptoms.
RESULTS: There were 23 trials from 22 publications (n = 819). The antidepressants involved were selective serotonin reuptake inhibitors, mirtazapine, reboxetine, mianserin, trazodone and ritanserin; trials on other antidepressants were not available. The overall standardised mean difference was moderate (-0.48) in favour of antidepressants and subgroup analysis revealed significant responses for fluoxetine, trazodone and ritanserin.
CONCLUSIONS: Antidepressants along with antipsychotics are more effective in treating the negative symptoms of schizophrenia than antipsychotics alone.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20807960     DOI: 10.1192/bjp.bp.109.067710

Source DB:  PubMed          Journal:  Br J Psychiatry        ISSN: 0007-1250            Impact factor:   9.319


  51 in total

Review 1.  Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review.

Authors:  Selene R T Veerman; Peter F J Schulte; Lieuwe de Haan
Journal:  Drugs       Date:  2017-09       Impact factor: 9.546

2.  Medicaid cost control measures aimed at second-generation antipsychotics led to less use of all antipsychotics.

Authors:  William B Vogt; Geoffrey Joyce; Jing Xia; Riad Dirani; George Wan; Dana P Goldman
Journal:  Health Aff (Millwood)       Date:  2011-12       Impact factor: 6.301

3.  Meta-analysis of the efficacy of adjunctive NMDA receptor modulators in chronic schizophrenia.

Authors:  Surendra P Singh; Vidhi Singh
Journal:  CNS Drugs       Date:  2011-10-01       Impact factor: 5.749

4.  Trends in the access to and the use of antipsychotic medications and psychotropic co-treatments in Asian patients with schizophrenia.

Authors:  Y-T Xiang; G S Ungvari; C U Correll; H F K Chiu; N Shinfuku
Journal:  Epidemiol Psychiatr Sci       Date:  2015-08-20       Impact factor: 6.892

Review 5.  Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials.

Authors:  Masahiro Nitta; Taishiro Kishimoto; Norbert Müller; Mark Weiser; Michael Davidson; John M Kane; Christoph U Correll
Journal:  Schizophr Bull       Date:  2013-05-29       Impact factor: 9.306

6.  In vivo imaging of brain microglial activity in antipsychotic-free and medicated schizophrenia: a [11C](R)-PK11195 positron emission tomography study.

Authors:  S E Holmes; R Hinz; R J Drake; C J Gregory; S Conen; J C Matthews; J M Anton-Rodriguez; A Gerhard; P S Talbot
Journal:  Mol Psychiatry       Date:  2016-10-04       Impact factor: 15.992

7.  Analysis of genome-wide association data highlights candidates for drug repositioning in psychiatry.

Authors:  Hon-Cheong So; Carlos Kwan-Long Chau; Wan-To Chiu; Kin-Sang Ho; Cho-Pong Lo; Stephanie Ho-Yue Yim; Pak-Chung Sham
Journal:  Nat Neurosci       Date:  2017-08-14       Impact factor: 24.884

Review 8.  Negative Symptoms and Cognitive Impairments in Schizophrenia: Two Key Symptoms Negatively Influencing Social Functioning.

Authors:  Koichi Kaneko
Journal:  Yonago Acta Med       Date:  2018-06-18       Impact factor: 1.641

9.  Comorbid Diabetes and Depression in a National Sample of Adults With Psychosis.

Authors:  Debra L Foley; Andrew Mackinnon; Vera A Morgan; David J Castle; Anna Waterreus; Cherrie A Galletly
Journal:  Schizophr Bull       Date:  2018-01-13       Impact factor: 9.306

Review 10.  Polypharmacy for schizophrenia.

Authors:  Jacob Ballon; T Scott Stroup
Journal:  Curr Opin Psychiatry       Date:  2013-03       Impact factor: 4.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.